6.28
price up icon7.17%   0.42
after-market アフターアワーズ: 6.28
loading
前日終値:
$5.86
開ける:
$5.84
24時間の取引高:
635.58K
Relative Volume:
2.46
時価総額:
$133.10M
収益:
$73.62M
当期純損益:
$-138.24M
株価収益率:
-0.9949
EPS:
-6.3125
ネットキャッシュフロー:
$-99.19M
1週間 パフォーマンス:
+4.15%
1か月 パフォーマンス:
-30.84%
6か月 パフォーマンス:
-45.06%
1年 パフォーマンス:
-26.29%
1日の値動き範囲:
Value
$5.72
$6.31
1週間の範囲:
Value
$5.70
$6.56
52週間の値動き範囲:
Value
$5.70
$17.80

Enanta Pharmaceuticals Inc Stock (ENTA) Company Profile

Name
名前
Enanta Pharmaceuticals Inc
Name
セクター
Healthcare (1176)
Name
電話
617 607 0800
Name
住所
500 ARSENAL STREET, WATERTOWN, MA
Name
職員
131
Name
Twitter
@EnantaPharma
Name
次回の収益日
2024-11-25
Name
最新のSEC提出書
Name
ENTA's Discussions on Twitter

ENTA を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
ENTA
Enanta Pharmaceuticals Inc
6.28 133.10M 73.62M -138.24M -99.19M -6.56
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
397.27 102.31B 10.63B -479.80M -1.35B -1.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
701.85 77.13B 13.85B 4.65B 3.32B 40.41
Biotechnology icon
ARGX
Argen X Se Adr
623.82 37.30B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
245.44 31.66B 2.09B -332.26M 16.06M -2.62
Biotechnology icon
BNTX
Biontech Se Adr
113.08 27.11B 3.30B -501.07M 1.03B -2.1146

Enanta Pharmaceuticals Inc Stock (ENTA) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2023-08-09 ダウングレード JP Morgan Neutral → Underweight
2023-08-08 ダウングレード Jefferies Buy → Hold
2022-12-09 開始されました H.C. Wainwright Buy
2022-07-06 アップグレード Evercore ISI In-line → Outperform
2022-06-01 アップグレード Evercore ISI Underperform → In-line
2021-10-07 開始されました Jefferies Buy
2021-09-09 開始されました SVB Leerink Mkt Perform
2021-01-29 アップグレード JP Morgan Underweight → Neutral
2020-11-24 開始されました Evercore ISI Underperform
2020-08-28 再開されました ROTH Capital Buy
2020-08-26 開始されました Piper Sandler Overweight
2020-07-27 アップグレード JMP Securities Mkt Perform → Mkt Outperform
2020-03-17 アップグレード Robert W. Baird Neutral → Outperform
2019-11-22 ダウングレード JMP Securities Mkt Outperform → Mkt Perform
2019-09-26 ダウングレード JP Morgan Neutral → Underweight
2019-05-24 開始されました Wolfe Research Outperform
2019-04-23 アップグレード Berenberg Hold → Buy
2018-12-13 開始されました Berenberg Hold
2018-06-06 開始されました ROTH Capital Buy
2018-02-08 ダウングレード JP Morgan Overweight → Neutral
2018-01-02 ダウングレード RBC Capital Mkts Outperform → Sector Perform
2017-11-21 繰り返されました RBC Capital Mkts Outperform
2017-09-15 開始されました RBC Capital Mkts Outperform
2017-07-11 アップグレード JMP Securities Mkt Perform → Mkt Outperform
2016-04-28 ダウングレード JMP Securities Mkt Outperform → Mkt Perform
2016-02-09 繰り返されました Barclays Underweight
2015-10-23 ダウングレード Barclays Equal Weight → Underweight
2015-10-23 アップグレード JMP Securities Mkt Perform → Mkt Outperform
すべてを表示

Enanta Pharmaceuticals Inc (ENTA) 最新ニュース

pulisher
Dec 19, 2024

Fmr LLC Purchases 7,839 Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) - Defense World

Dec 19, 2024
pulisher
Dec 17, 2024

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 27,597 Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) - Defense World

Dec 17, 2024
pulisher
Dec 17, 2024

Charles Schwab Investment Management Inc. Sells 1,649 Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) - Defense World

Dec 17, 2024
pulisher
Dec 15, 2024

Enanta Pharmaceuticals' SWOT analysis: RSV pipeline progress buoys stock outlook - Investing.com

Dec 15, 2024
pulisher
Dec 14, 2024

(ENTA) Technical Data - Stock Traders Daily

Dec 14, 2024
pulisher
Dec 13, 2024

Enanta stock touches 52-week low at $6.36 amid market challenges - Investing.com Canada

Dec 13, 2024
pulisher
Dec 13, 2024

FY2025 Earnings Estimate for ENTA Issued By Leerink Partnrs - Defense World

Dec 13, 2024
pulisher
Dec 12, 2024

Leerink Partnrs Has Positive Outlook of ENTA FY2025 Earnings - MarketBeat

Dec 12, 2024
pulisher
Dec 11, 2024

Enanta Pharmaceuticals CFO Paul Mellett sells shares worth $20,883 By Investing.com - Investing.com Canada

Dec 11, 2024
pulisher
Dec 11, 2024

Enanta Pharmaceuticals' chief scientific officer sells $20,883 in stock By Investing.com - Investing.com Canada

Dec 11, 2024
pulisher
Dec 11, 2024

Enanta Pharmaceuticals CFO Paul Mellett sells shares worth $20,883 - Investing.com

Dec 11, 2024
pulisher
Dec 11, 2024

Enanta Pharmaceuticals' chief scientific officer sells $20,883 in stock - Investing.com

Dec 11, 2024
pulisher
Dec 11, 2024

Point72 Asset Management L.P. Buys New Holdings in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) - MarketBeat

Dec 11, 2024
pulisher
Dec 10, 2024

Enanta Pharmaceuticals chief scientific officer sells shares worth $20,883 By Investing.com - Investing.com Nigeria

Dec 10, 2024
pulisher
Dec 10, 2024

Enanta Pharmaceuticals' chief product strategy officer sells $18,400 in stock By Investing.com - Investing.com Canada

Dec 10, 2024
pulisher
Dec 10, 2024

Enanta Pharmaceuticals CEO sells $41,444 in stock By Investing.com - Investing.com Nigeria

Dec 10, 2024
pulisher
Dec 10, 2024

Enanta Pharmaceuticals CFO sells shares worth $20,883 - Investing.com

Dec 10, 2024
pulisher
Dec 10, 2024

Enanta Pharmaceuticals CEO sells $41,444 in stock - Investing.com

Dec 10, 2024
pulisher
Dec 10, 2024

Enanta Pharmaceuticals chief business officer sells $18,400 in stock By Investing.com - Investing.com Nigeria

Dec 10, 2024
pulisher
Dec 10, 2024

Enanta Pharmaceuticals CFO sells shares worth $20,883 By Investing.com - Investing.com Nigeria

Dec 10, 2024
pulisher
Dec 10, 2024

Enanta Pharmaceuticals chief business officer sells $18,400 in stock - Investing.com

Dec 10, 2024
pulisher
Dec 10, 2024

Enanta Pharmaceuticals' chief product strategy officer sells $18,400 in stock - Investing.com

Dec 10, 2024
pulisher
Dec 10, 2024

Enanta’s zelicapavir shows promise in paediatric respiratory syncytial virus trial - Yahoo Finance

Dec 10, 2024
pulisher
Dec 09, 2024

Enanta logs phase II RSV win with zelicapavir - BioWorld Online

Dec 09, 2024
pulisher
Dec 09, 2024

Enanta Pharmaceuticals Sees Positive Topline Results for RSV Drug Trials - MarketWatch

Dec 09, 2024
pulisher
Dec 09, 2024

LogoEnanta Pharmaceuticals Announces Positive Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV) - Business Wire

Dec 09, 2024
pulisher
Dec 09, 2024

Enanta Pharmaceuticals to Present Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for Respiratory Syncytial Virus (RSV) - BioSpace

Dec 09, 2024
pulisher
Dec 09, 2024

Enanta's RSV Drug Zelicapavir Shows Strong Antiviral Effects in Landmark Pediatric Trial - StockTitan

Dec 09, 2024
pulisher
Dec 06, 2024

Enanta Pharma to Unveil Breakthrough RSV Pediatric Trial ResultsKey Phase 2 Data Coming - StockTitan

Dec 06, 2024
pulisher
Dec 05, 2024

Enanta stock touches 52-week low at $7.99 amid market challenges - Investing.com Nigeria

Dec 05, 2024
pulisher
Dec 04, 2024

Erste Asset Management GmbH Purchases New Stake in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) - MarketBeat

Dec 04, 2024
pulisher
Dec 01, 2024

Enanta Pharmaceuticals (FRA:9EP) 3-Year FCF Growth Rate : -9.20% (As of Sep. 2024) - GuruFocus.com

Dec 01, 2024
pulisher
Dec 01, 2024

Caligan Partners LP Cuts Holdings in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) - MarketBeat

Dec 01, 2024
pulisher
Dec 01, 2024

Analysts Set Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) PT at $19.50 - MarketBeat

Dec 01, 2024
pulisher
Nov 30, 2024

Enanta Pharmaceuticals Initiates Phase 1 Study of MRSA Infection Candidate EDP-788 - Marketscreener.com

Nov 30, 2024
pulisher
Nov 30, 2024

Enanta Pharmaceuticals (NASDAQ:ENTA) Receives Market Outperform Rating from JMP Securities - Defense World

Nov 30, 2024
pulisher
Nov 30, 2024

Analysts Have Been Trimming Their Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Price Target After Its Latest Report - Simply Wall St

Nov 30, 2024
pulisher
Nov 29, 2024

Enanta Pharmaceuticals’ Reduced Reporting: Potential Impact on Investor Appeal and Stock Volatility - Yahoo Finance

Nov 29, 2024
pulisher
Nov 28, 2024

Enanta Pharmaceuticals' SWOT analysis: RSV pipeline and cash position fuel stock outlook - Investing.com

Nov 28, 2024
pulisher
Nov 28, 2024

ENTA (Enanta Pharmaceuticals) Accounts Receivable : $6.65 Mil (As of Sep. 2024) - GuruFocus.com

Nov 28, 2024
pulisher
Nov 28, 2024

Robert W. Baird Has Lowered Expectations for Enanta Pharmaceuticals (NASDAQ:ENTA) Stock Price - Defense World

Nov 28, 2024
pulisher
Nov 27, 2024

Enanta Pharmaceuticals Inc. (ENTA) reports earnings - Quartz

Nov 27, 2024
pulisher
Nov 27, 2024

Benign Growth For Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Underpins Stock's 27% Plummet - Simply Wall St

Nov 27, 2024
pulisher
Nov 27, 2024

Enanta Pharmaceuticals (STU:9EP) Cash Flow from Operations : €-83.19 Mil (TTM As of Jun. 2024) - GuruFocus.com

Nov 27, 2024
pulisher
Nov 27, 2024

Enanta stock touches 52-week low at $8.45 amid market challenges - Investing.com Canada

Nov 27, 2024
pulisher
Nov 26, 2024

4 Analysts Assess Enanta Pharma: What You Need To Know - Benzinga

Nov 26, 2024
pulisher
Nov 26, 2024

Leerink raises Enanta price target to $12 from $10, keeps rating - Investing.com UK

Nov 26, 2024

Enanta Pharmaceuticals Inc (ENTA) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$17.87
price down icon 2.88%
$68.84
price up icon 2.65%
$39.39
price down icon 0.43%
$359.58
price down icon 0.16%
$176.50
price up icon 1.02%
$113.08
price up icon 1.56%
大文字化:     |  ボリューム (24 時間):